Hege Garelius - Concepedia

Author

Hege Garelius

Sahlgrenska University Hospital ORCID

Also Known As

E. Hesse Sundin, H Garelius, H. Garelius, H. Gravdahl Garelius, Hege Garelius, Hege Gravdahl Garelius, Å Derolf

Publications

Citations

H-Index

Concepts

All Affiliations

Sahlgrenska University Hospital Karolinska Institutet Karolinska University Hospital Skåne University Hospital Lund University

About

Hege Garelius is an author at Sahlgrenska University Hospital specializing in medicine, hematology, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	4	4	181
2	Health Sciences	2	2	71
3	Public Health	2	2	110
4	Epidemiology	2	2	110
5	Blood Transplantation	1	1	39

Hege Garelius

Publications

879

Citations

H-Index

Page 1

	Year	Citations
Characterization and prognostic features of secondary acute myeloid leukemia in a population‐based setting: <scp>A</scp> report from the <scp>S</scp>wedish <scp>A</scp>cute <scp>L</scp>eukemia <scp>R</scp>egistry Erik Hulegårdh, Christer Nilsson, Vladimir Lazarević, American Journal of Hematology	2014	271
Quality of life, physical function and MRI T2* in elderly low-risk MDS patients treated to a haemoglobin level of ≥120 g/L with darbepoetin alfa ± filgrastim or erythrocyte transfusions Herman Nilsson‐Ehle, Gunnar Birgegård, Jan Samuelsson, European Journal Of Haematology	2011	62
Early death rates remain high in high-risk APL: update from the Swedish Acute Leukemia Registry 1997–2013 Sören Lehmann, Stefan Deneberg, P Antunović, Leukemia Hematological MalignancyHigh-risk AplEarly Death RatesMedicineMixed-phenotype Acute Leukemia	2017	58
Limited clinical efficacy of azacitidine in transfusion-dependent, growth factor-resistant, low- and Int-1-risk MDS: Results from the nordic NMDSG08A phase II trial Magnus Tobiasson, I Dybedahl, Mette Skov Holm, Blood Cancer Journal	2014	55
Characterization of therapy-related acute myeloid leukemia: increasing incidence and prognostic implications Christer Nilsson, Fredrika Linde, Erik Hulegårdh, Haematologica Mixed-phenotype Acute LeukemiaEpidemiology Of CancerPathologyCancer RegistrationPharmacotherapy	2022	52
Clinical effect of increasing doses of lenalidomide in high-risk myelodysplastic syndrome and acute myeloid leukemia with chromosome 5 abnormalities Lars Möllgård, Leonie Saft, Marianne Bach Treppendahl, Haematologica	2011	51
Labile plasma iron levels predict survival in patients with lower-risk myelodysplastic syndromes Louise de Swart, Chloé Reiniers, Timothy Bagguley, Haematologica	2017	44
Prognostic scoring systems for myelodysplastic syndromes (<scp>MDS</scp>) in a population‐based setting: a report from the Swedish <scp>MDS</scp> register Daniel Moreno Berggren, Yasin Folkvaljon, Marie Engvall, British Journal of Haematology	2018	44
Secondary Acute Myeloid Leukemia and the Role of Allogeneic Stem Cell Transplantation in a Population-Based Setting Christer Nilsson, Erik Hulegårdh, Hege Garelius, Biology of Blood and Marrow Transplantation Secondary AmlMixed-phenotype Acute LeukemiaImmunologyPathologyImmunotherapy	2019	39
A pilot phase I dose finding safety study of the thrombopoietin‐receptor agonist, eltrombopag, in patients with myelodysplastic syndrome treated with azacitidine Tobias Svensson, Onima Chowdhury, Hege Garelius, European Journal Of Haematology	2014	33

Page 1